Lantus History and Development: How Insulin Glargine Changed Basal Insulin Therapy

The Problem Insulin Glargine Was Built to Solve

Before insulin glargine, people with diabetes relying on intermediate-acting NPH insulin faced a difficult reality: unpredictable absorption, a pronounced peak at 4 to 8 hours, and the need for twice-daily injections that still left overnight glucose control unreliable. NPH's crystalline protamine suspension dissolved unevenly from the subcutaneous depot, producing variable pharmacokinetics that contributed to both nocturnal hypoglycemia and fasting hyperglycemia [1].

The clinical burden was measurable. A meta-analysis published in Diabetes Care found that NPH-based regimens carried a significantly higher rate of nocturnal hypoglycemia compared to long-acting analogs, with relative risk reductions of 40% to 50% favoring glargine in multiple trials [2]. Endocrinologists wanted a basal insulin that could mimic the steady, low-level secretion of a healthy pancreas across a full 24-hour period. No product on the market in the 1990s could do that reliably.

The design brief was specific: create a molecule that forms a stable depot after injection, releases insulin monomers at a near-constant rate, and does not require resuspension or mixing. That challenge fell to a team of protein chemists at Hoechst AG in Frankfurt, Germany.

Molecular Engineering: Two Changes That Made the Difference

Insulin glargine's design is a case study in targeted protein engineering. The Hoechst team, led by researchers including Georg Seipke and Ekkehard Barth, made exactly two modifications to the human insulin molecule [3].

First, they replaced the asparagine at position A21 with glycine. This single substitution eliminated an acid-labile deamidation site that would have destabilized the molecule in the acidic formulation (pH 4.0) required for solubility. Second, they added two arginine residues to the C-terminus of the B-chain at positions B31 and B32. These positively charged arginines shifted the isoelectric point from approximately pH 5.4 (native human insulin) to pH 6.7 [3].

That shift is the entire mechanism. At the formulation pH of 4.0, glargine remains fully dissolved in the vial or pen cartridge. When injected into subcutaneous tissue at physiologic pH (approximately 7.4), the molecule crosses its isoelectric point and precipitates into amorphous microprecipitates. These microprecipitates then slowly dissolve, releasing insulin glargine monomers into the bloodstream at a steady rate over roughly 24 hours [4].

The result is a pharmacokinetic profile with no pronounced peak. Euglycemic clamp studies demonstrated that glargine produces a relatively flat insulin activity curve, with a duration of action between 20 and 26 hours in most patients [4]. This was a stark departure from NPH.

From the Lab to FDA Approval: 1988 to 2000

The timeline from molecular concept to marketed drug spanned about twelve years. Hoechst AG filed the earliest patent applications for insulin glargine in the late 1980s, with key composition-of-matter patents granted in the early 1990s [5]. Preclinical pharmacology studies confirmed the peakless absorption profile in animal models.

Clinical development began in the mid-1990s. Hoechst merged with Rhône-Poulenc in 1999 to form Aventis, which carried the glargine program through its Phase III trials. The key registration studies enrolled patients with both type 1 and type 2 diabetes across North America and Europe.

A representative Phase III trial published by Ratner et al. in Diabetes Care (2000) randomized 518 patients with type 1 diabetes to insulin glargine once daily at bedtime versus NPH once or twice daily. Glargine produced comparable HbA1c reductions but significantly fewer episodes of nocturnal hypoglycemia (33.2% vs. 40.2% of patients reporting confirmed nocturnal events, P=0.0143) [6].

The FDA approved Lantus on April 20, 2000, making it the first long-acting insulin analog available in the United States [7]. The European Medicines Agency followed with approval later that year. Sanofi (which absorbed Aventis in 2004) would market Lantus globally, and the drug rapidly became the world's best-selling insulin product.

How Insulin Glargine Works in the Body

Once injected subcutaneously, glargine microprecipitates dissolve gradually into dimers and monomers. The active metabolites, primarily M1 (21A-Gly-insulin) and M2 (21A-Gly-des-30B-Thr-insulin), bind to the insulin receptor on target cells in muscle, liver, and adipose tissue [8].

Binding activates the insulin receptor tyrosine kinase, triggering phosphorylation of insulin receptor substrates (IRS-1 and IRS-2). This initiates two major downstream cascades. The PI3K-Akt pathway drives translocation of GLUT4 glucose transporters to the cell surface in skeletal muscle and adipose tissue, enabling glucose uptake. Simultaneously, Akt-mediated signaling suppresses hepatic glucose output by inhibiting glycogenolysis and gluconeogenesis [8].

The net effect is a steady suppression of fasting hepatic glucose production. Unlike rapid-acting insulins that target postprandial spikes, glargine provides a baseline level of insulin activity that prevents glucose from rising between meals and overnight. This basal-bolus separation became a defining principle of modern insulin therapy.

One pharmacologic nuance deserves attention. Glargine's metabolite M1 has an IGF-1 receptor binding affinity similar to native human insulin, which was relevant to early safety discussions about mitogenicity. The ORIGIN trial, discussed below, was partly designed to address this concern [9].

The ORIGIN Trial: Cardiovascular Safety at Scale

The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial remains the largest and most consequential study in glargine's clinical history. Published in the New England Journal of Medicine in June 2012, ORIGIN randomized 12,537 people with early type 2 diabetes, impaired fasting glucose, or impaired glucose tolerance to insulin glargine (targeting a fasting glucose <95 mg/dL) versus standard care [10].

The median follow-up was 6.2 years. The primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 2.94 per 100 person-years in the glargine group versus 2.85 per 100 person-years in the standard-care group (hazard ratio 1.02, 95% CI 0.94 to 1.11) [10]. This confirmed cardiovascular neutrality.

ORIGIN also addressed the cancer signal that had troubled regulators. The incidence of any cancer was 1.32 per 100 person-years with glargine versus 1.26 per 100 person-years with standard care (HR 1.00, 95% CI 0.88 to 1.13), effectively ruling out a clinically meaningful cancer risk [10].

Dr. Hertzel Gerstein, the ORIGIN principal investigator, stated at the time of publication: "These findings indicate that early use of basal insulin glargine had a neutral effect on cardiovascular outcomes and cancers over more than six years" [10]. The trial's size and duration set a benchmark that subsequent basal insulin programs (degludec's DEVOTE, for instance) would follow.

A second finding from ORIGIN was clinically instructive. The rate of severe hypoglycemia was modestly but significantly higher with glargine (1.00 vs. 0.31 per 100 person-years). Weight gain was also greater in the glargine arm (mean +1.6 kg vs. -0.5 kg). These tradeoffs became part of the risk-benefit conversation that clinicians have had with patients for the past decade [10].

Biosimilar Competition and Market Evolution

Lantus's commercial dominance began to erode in 2015 when Eli Lilly and Boehringer Ingelheim launched Basaglar, the first follow-on insulin glargine product in the United States. Basaglar was approved under the 505(b)(2) regulatory pathway rather than the formal biosimilar (351(k)) route, though it contained the identical glargine molecule at the same 100 units/mL concentration [11].

The true biosimilar milestone came in 2020 when the FDA approved Semglee (insulin glargine-yfgn, Mylan/Viatris), and in 2021 designated it the first interchangeable biosimilar insulin in the United States [12]. Interchangeability meant pharmacists could substitute Semglee for Lantus without prescriber intervention, a regulatory distinction that had practical implications for cost and access.

Sanofi responded to biosimilar pressure partly by shifting its own portfolio. Toujeo (insulin glargine U-300), approved in 2015, concentrated the same molecule into a threefold higher concentration (300 units/mL). The EDITION clinical program demonstrated that Toujeo provided comparable glycemic control to Lantus with a lower incidence of confirmed nocturnal hypoglycemia, particularly in type 2 diabetes (EDITION 1: nocturnal confirmed hypoglycemia rate ratio 0.64, P<0.0001) [13].

By 2024, the American Diabetes Association's Standards of Care listed insulin glargine (both U-100 and U-300) among preferred basal insulins, alongside insulin degludec, reflecting their favorable pharmacokinetic profiles relative to NPH [14].

Glargine's Place in Modern Insulin Therapy

Insulin glargine did not merely replace NPH. It restructured how clinicians think about basal insulin initiation and titration. The predictable 24-hour profile enabled simpler titration algorithms. The Treat-to-Target trial (Riddle et al., Diabetes Care 2003) demonstrated that a forced titration algorithm using bedtime glargine brought 58% of type 2 diabetes patients to an HbA1c <7% within 24 weeks, with a low rate of severe hypoglycemia (1.7 events per 100 patient-years) [15].

Dr. Matthew Riddle, lead author of the Treat-to-Target study, noted: "A simple algorithm for insulin glargine titration, directed by the patient using self-monitored fasting glucose values, can achieve recommended glycemic targets in a majority of patients" [15]. That patient-directed titration approach became standard practice and was adapted into the ADA's basal insulin initiation guidelines.

The drug also became a backbone of combination therapy. GLP-1 receptor agonist and basal insulin fixed-ratio combinations (Soliqua, which pairs glargine with lixisenatide) emerged directly from the clinical experience showing complementary mechanisms between basal insulin's fasting glucose control and GLP-1 agonists' postprandial and weight effects [16].

Thirty-eight years after its initial conception at Hoechst AG, insulin glargine remains among the most prescribed insulins worldwide. Its molecular design principle (shifting the isoelectric point to create a subcutaneous depot) has been applied to subsequent analogs, and its clinical evidence base, anchored by ORIGIN's 12,537 patients followed for 6.2 years, set the standard for cardiovascular outcomes data that regulators now expect from all new diabetes therapies.

The starting dose for most adults with type 2 diabetes is 10 units subcutaneously once daily, titrated by 2 units every 3 days to a fasting plasma glucose target of 80 to 130 mg/dL per current ADA recommendations [14].